CClinicalTrials.gg
Not yet recruitingNCT06554457ORORAUpdated Aug 15, 2024

Post Surgical Multimodal Analgesia With Oral Strong Opioids

An observational study in Orthopedic Procedures, Arthroplasty and Fracture Fixation, sponsored by Tri-Service General Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Tri-Service General Hospital · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Study summary

This is a prospective observational case study, focusing on the clinical effectiveness of oral strong opioids for pain management following common orthopedic surgeries.The study aims to evaluate the effectiveness of multimodal analgesia with oral strong opioids, reduce common opioid-related side effects, and improve patient compliance and satisfaction.

02

Conditions studied

  • Orthopedic Procedures
  • Arthroplasty
  • Fracture Fixation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients who are hospitalized for the following surgical treatment may be enrolled:

  1. Fracture of upper or lower limbs or pelvis requiring internal fixation surgery
  2. Spinal fusion surgery
  3. Joint replacement surgery

Inclusion criteria

  1. Aged 18 or older
  2. Must undergo one of the following treatments:

(1) Fracture of upper or lower limbs or pelvis requiring internal fixation surgery (2) Spinal fusion surgery (3) Joint replacement surgery 3. Requiring multimodal analgesics for postoperative pain control, with oral strong opioids as the primary opioid analgesic, as assessed by his/her physician.

  1. Voluntarily sign the informed consent form and agree to the collection of clinical questionnaires and medical-related information for this study.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have not received any or have only received oral potent opioids for no more than 1 day during the postoperative hospitalization period (including those known to be intolerant or allergic to opioid medications).
  2. Patients who have received or are expected to use long-acting opioid injections within 7 days before surgery or during the postoperative hospitalization period.
  3. Patients who use patient-controlled analgesics for pain control after surgery.
  4. Patients with a history of substance abuse or who require continuous treatment with other opioid receptor agonists or antagonists (such as naloxone or methadone).
  5. Patients with a history of mental illness who continue to require medication control from 28 days before surgery and until discharge.
  6. Other cases deemed ineligible by the study investigator.
04

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Fracture fixation

    Fracture of upper or lower limbs or pelvis requiring internal fixation surgery

    Drug: Multimodal analgesia with oral strong opioids

  • Spinal fusion

    Spinal fusion surgery

    Drug: Multimodal analgesia with oral strong opioids

  • Arthroplasty

    Joint replacement surgery

    Drug: Multimodal analgesia with oral strong opioids

Interventions

  • DrugMultimodal analgesia with oral strong opioids

    Physician's choice of post-surgical multimodal analgesia with an oral strong opioid as the backbone analgesics

05

What researchers measure

Primary outcomes

  1. Change in pain scores from baseline

    Assess the efficacy of including oral strong opioids in multimodal pain control. For this objective, we will observe changes in pain scores among participants during postoperative treatment.

    Time frame: Twice daily during hospitalization (approximately within 1 week), at the first return 1 day visit and at 3 months after surgery

Secondary outcomes

  1. Occurence of adverse events

    Avoid common adverse reactions associated with traditional morphine-like drugs, such as respiratory depression and addiction, to enhance treatment safety and patient comfort. We will monitor the occurrence rate of adverse reactions related to oral potent opioids.

    Time frame: During hospitalization (approximately within 1 week)

  2. Compliance of oral strong opioids

    Improvement the convenience of analgesic medication by transitioning from injections to oral administration, making it easier for patients to accept and adhere to the treatment plan. The compliance rate of oral strong opioids will be measured.

    Time frame: During hospitalization (approximately within 1 week)

  3. Physician's global impression - improvement scale(CGI-I)

    Effectiveness of the pain control will be assessed by a 7-point scale that requires the clinician to assess how much the patient's illness has improved or worsened relative to a baseline state at the beginning of the intervention. Scale 1= Very much improved and scale 7 = very much worse

    Time frame: During hospitalization (approximately within 1 week), at the first return 1 day visit and at 3 months after surgery

  4. Satisfation of the pain control as per patients' report outcome

    Enhance patient acceptance of the treatment by using oral administration, boosting confidence in the treatment plan and increasing adherence and effectiveness. Patient satisfaction and pain improvement will be assessed through a 5-point scale questionnaire. 1=very much discontent, 2=discontent, 3=fair, 4=satisfied, 5=very much satisfied.

    Time frame: End of hospitalization (approximately 1 week after surgery)

06

Study locations

1 site
  • TriService General Hospital
    Taipei, 114, Taiwan
07

References and documents

Individual participant data

Plan to share: No — Only anonymized and de-identified information can be collected from the participants as per institutional review board's approval.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06554457
Lead sponsor
Tri-Service General Hospital
Responsible party
Tsu-Te Yeh (Attending Surgeon, Tri-Service General Hospital) — Principal investigator
First posted
Aug 15, 2024
Start date
Aug 12, 2024 (estimated)
Primary completion
Jul 31, 2025 (estimated)
Completion
Jul 31, 2025 (estimated)
Last update
Aug 15, 2024

Study contacts

Tsu-te Yeh, MD
Contact
tsutey@gmail.com
886-2-87923311 ext. 88081
Tim TH Wang, PhD
Contact
asahi.tim@gmail.com
886-939081832
Tsu-te Yeh, MD
principal investigator · TriService General Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion